Pre-CAAP Company: Akira is Expanding Across Canada
OBIO Pre-CAAP, Akira, is planning to expand into 3 additional provinces: Quebec, Alberta, and BC. In addition to their existing coverage in Ontario, this will allow them to provide on-demand care to 90% of the Canadian population.
Pre-CAAP Company: Tranqool Featured on CP24 About Tips for Dealing With Seasonal Affective Disorder (SAD)
OBIO Pre-CAAP company, TranQool, has been featured on CP24 chatting about tips for dealing with Seasonal Affective Disorder (SAD).
OBIO® CEO Gail Garland Selected as Founding Member of Springboard Enterprises Canadian Advisory Council
WASHINGTON, D.C. (January 19, 2017) – Springboard Enterprises (www.sb.co), a venture catalyst dedicated to promoting high growth potential companies led by women, announced the formation of the Springboard Canadian Advisory Council and its seven Founding Members. The Founding Members are connected influencers, investors, and innovators from the technology and life science sectors across Canada.
Pre-CAAP Company: Akira Featured in the Globe and Mail
OBIO Pre-CAAP, Akira, has partnered with Uberflip, a Toronto-based firm that builds content marketing platforms offering benefits specially tailored to Gen Yers.
CAAP Company: Eve Medical Named Reader's Digest Health Hero
Former OBIO CAAP company, Eve Medical, has been named as one of Reader's Digest Canadian Health Heroes and a need to know company.
CAAP Company: TECLA Features Switch Control and Platform Switching as an Essential Part of Independence at Home
OBIO CAAP Company, TECLA, features Switch Control and Platform Switching as an essential part of independence at home.
Pre-CAAP Company: Pathcore Wins 1st Place at RESI Innovation Challenge in San Francisco
Pathcore won 1st Place at RESI Innovation Challenge in San Francisco!
Taiwanese Multinational Wistron Visits Toronto
An Executive Team from Taiwanese multinational, Wistron, will be visiting Canada with stops in Toronto, Ottawa and Montreal during the week of Feb 13, 2017 (Feb 13-14 in Toronto). Wistron is seeking partnerships including JVs, equity investments and distribution in sectors of medical technology, artificial intelligence, machine learning and Big Data.
MRIS in partnership with the Consulate General of China in Toronto will host the 6th Ontario-China Research and Innovation Collaboration Forum on May 15
You are invited to participate in this year’s biggest Ontario-China collaboration event in Toronto. Registration is free!
The Ministry of Research, Innovation and Science in partnership with the Consulate General of China in Toronto will host the 6th Ontario-China Research and Innovation Collaboration Forum (May 15) in conjunction with the 2017 OCE Discovery event to further strengthen collaboration under the Ontario-China MOU on Research and Innovation signed between the Government of Ontario and the Ministry of Science and Technology of China.
China is investing significantly in innovation to drive the economic growth. This provides golden opportunities for all of Ontario’s technology sectors. We look forward to your participation and engagement.
The Honourable Minister Reza Moridi of the Ministry of Research, Innovation and Science and the Consul General from the Consulate General of China, have been invited to participate in the event and provide opening remarks at the Forum.
Pre-CAAP Company: Winterlight Labs Featured in WIRED
OBIO Pre-CAAP company Winterlight Labs has been featured in WIRED alongside cutting-edge tech for detecting autism and genetic disorders.
Springboard Enterprises: Applications Open for Health Innovation Hub
The Health Innovation Hub is Springboard’s program for women-led companies seeking growth funding and expert connections to develop solutions in pharma, including new drugs, diagnostics, pharma technologies, and drug-delivery devices.
Exact Imaging Secures CDN $21.5 Million to Support Commercialization of Its Exactvu™ Micro-Ultrasound
TORONTO, CANADA -- (January 5, 2017) Exact Imaging (www.exactimaging.com), the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has secured CDN $21.5 million in a Series C investment to commercialize its ExactVu™ micro-ultrasound system.
Versant Ventures Closes 6th Healthcare Fund
Versant Ventures has announced the close of its newest fund, Versant Venture Capital VI, at its hard cap of CAD538 million (USD400 million). Versant will use its diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics.
OxiLight Inc Releases New Video
OBIO Pre-CAAP company, OxiLight Inc, has released a new video about their innovative wound imaging system for diabetic foot ulcers and peripheral vascular disease and how their technology can save lives and limbs
The ChipCare Team Grows
Former OBIO CAAP company, ChipCare Corporation, a Toronto-based start-up company creating a point-of-care platform that will bring lifesaving diagnostics to millions without access, has expanded its team
Intronix Technologies Upgrades
Former OBIO CAAP company, Intronix Technologies, have upgraded their Myoguide Stimulator capability.
Eve Medical Featured in MIT Technology Review
Eve Medical is as an up and coming technology trend to watch in women's health.
Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Therapeutics Deals
TORONTO & MONTREAL & VANCOUVER, British Columbia December 19, 2016 -Versant Ventures today announced that Toronto-based portfolio company Northern Biologics Inc. has executed a transformational deal that expands its pipeline and financial resources, bringing commitments to Versant’s Canadian biotech portfolio to over CAD$500 million.
MDCC Website Relaunched
On December 15 MDCC re-launched their website!
Click here to check out the new website
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
LEVERKUSEN, Germany and BOSTON and NEW YORK and TORONTO and KYOTO, Japan, Dec. 12, 2016 - Bayer AG and Versant Ventures today announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. BlueRock Therapeutics will be led by a world-class team and has assembled its platform through a series of strategic partnerships with academia and industry.